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Efficacy of orally administered maropitant citrate in preventing vomiting
associated with hydromorphone administration in dogs
Abstract
Objective—To evaluate the effectiveness of orally administered maropitant citrate in preventing vomiting
after hydromorphone hydrochloride administration in dogs.
Design—Randomized, blinded, prospective clinical study.
Animals—40 dogs with American Society of Anesthesiologists status of I or II, > 6 months of age, and
weighing between 24 and 58.2 kg (52.8 and 128.04 lb).
Procedures—Dogs were randomly selected to receive maropitant (2.0 to 4.0 mg/kg [0.9 to 1.8 mg/lb]) or
placebo (lactose monohydrate) orally 2 hours prior to receiving hydromorphone (0.1 mg/kg [0.045 mg/lb],
IM). A blinded observer recorded the occurrence of vomiting or signs of nausea (eg, salivation or lip-licking)
during a 30-minute period after hydromorphone administration. Two-tailed Fisher exact tests were used to
compare the incidences of vomiting and signs of nausea with or without vomiting between treatment groups.
Results—Of the 20 dogs receiving maropitant, none vomited but 12 (60%) developed signs of nausea. Of the
20 dogs receiving placebo, 5 (25%) vomited and 11 (55%) developed signs of nausea; overall, 16 of 20 (80%)
dogs in the placebo treatment group vomited or developed signs of nausea. Compared with the effects of
placebo, maropitant significantly decreased the incidence of vomiting but not signs of nausea in dogs
administered hydromorphone.
Conclusions and Clinical Relevance—Among the 40 study dogs, the incidence of vomiting associated with
hydromorphone administration was 25%. Oral administration of maropitant prevented vomiting but not signs
of nausea associated with hydromorphone administration in dogs.
Disciplines
Comparative and Laboratory Animal Medicine | Small or Companion Animal Medicine | Veterinary
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Efficacy of orally administered maropitant citrate 
in preventing vomiting associated 
with hydromorphone administration in dogs 
Bonnie L. Hay Kraus, DVM 
Objective-To evaluate the effectiveness of ora lly administered maropitant citrate in pre-
venting vomiting after hydromorphone hydrochloride admin is trat ion in dogs. 
Design-Randomized, blinded, prospective clinical study. 
Animals-40 dogs with American Society of Anesthesiolog ists status of I or II, > 6 months 
of age, and we igh ing between 24 and 58.2 kg (52.8 and 128.04 lb) . 
Procedures-Dogs were randomly selected to receive maropitant (2.0 to 4.0 mg/kg [0.9 
to 1.8 mg/lb]) or placebo (lactose monohydrate) orally 2 hours prio r to rece iving hydromo r-
phone (0.1 mg/kg [0 045 mg/lb], IM). A blinded observer recorded the occurrence of vomit-
ing or signs of nausea (eg, salivation or lip-licking) during a 30-minute period after hydro mor-
phone administrat ion. Two-tailed Fisher exact tests were used to compare the incidences of 
vomiting and signs of nausea with or without vomiting between treatment groups. 
Results-Of the 20 dogs receiving maropitant, none vom ited but 12 (60 %) developed s igns 
of nausea. Of the 20 dogs receiving placebo, 5 (25%) vomited and 11 (55%) developed 
signs of nausea; overall , 16 of 20 (80%) dogs in the placebo treatment group vomited or 
developed signs of nausea. Compared with the effects of placebo, maropitant s ignificantly 
decreased the incidence of vomiting but not signs of nausea in dogs admin istered hydro-
morphone. 
Conclusions and Clinical Relevance-Among the 40 study dogs, the incidence of vomit-
ing associated w ith hydromorphone administration was 25 %. Oral adm inistration of ma-
rop itant prevented vomiting but not signs of nausea associated with hydromorphone ad-
ministration in dogs. (J Am Vet Med Assoc 2014;244:1164-1169) 
H ydromorphone, a synthetic µ-opioid receptor ago-nist that is approximately 5 to 7 times as potent as 
morphine , is commonly used as an anesthetic premedi-
cation agent alone or in combination with tranquilizers 
or sedatives, as part of a regimen for induction of an-
esthesia in higher-risk patients, and as an intraopera-
tive and postoperative analgesic agent. 1 This versatility, 
the avoidance of histamine-mediated vasodilation and 
hypotension, and the drug's low cost contribute to the 
widespread use of hydromorphone in veterinary medi-
cine in North America. 2 
Along with analgesia, hydromorphone is associ-
ated with various adverse effects. These may include 
respiratory depression, bradycardia, behavioral changes 
(including sedation, dysphoria, or excitement) , urine 
retention, and decreased urine production and gastro-
intestinal effects (including salivation and other signs 
of nausea , vomiting, and defecation). 3- 5 In dogs, the 
incidence of vomiting associated with hydromorphone 
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administration has been reported to be 0% to 100%, 
depending on the study conditions, study population, 
dose and route of administration , and concurrent use of 
acepromazine. 2·6-9 In general, the incidence of vomiting 
is decreased with higher doses and IV administration 
of hydromorphone, with concurrent administration o f 
acepromazine, and in purpose-bred or research condi-
tioned clogs from which food had not been withheld 
versus clinical patients undergoing elective surgery.2·6-9 
Avoidance or prevention of perioperative vomiting 
and nausea is an important objective in human medi-
cine and may also be desirable in many instances in 
veterinary medicine. Vomiting and regurgitation , es-
pecially when associated with anesthesia and the use 
of hyclromorphone, have been documented as risk fac-
tors for the development of aspiration pneumonia in 
dogs. 10-14 Underlying gastrointestinal tract dysfunction , 
along with upper airway abnormalities and surgical 
intervention, put dogs of brachycephalic breeds at in-
creased risk of perianesthesia vomiting, regurgitation, 
aspiration pneumonia, and increased mortality rate. 15·16 
Vomiting may also be undesirable in certain clinical 
cases wherein increases in intraocular or intracranial 
pressure caused by vomiting may lead to increased pa-
tient morbidity. 11- 20 
Maropitant is a neurokinin-1 receptor antagonist 
that has been approved to prevent and treat vomiting 
in dogs. It is used clinically to treat vomiting attrib-
utable to a wide range of clinical causes. 2 1·22 It is also 
highly effective in preventing vomiting secondary to a 
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broad spectrum of emetic stimuli, including cisplatin, 
apomorphine, copper sulfate, and motion sickness.2:>-26 
Results of a previous study9 in dogs indicate that ma-
ropitant citrate (1.0 mg/kg [0.45 mg/lb], SC) injected 1 
hour prior to premedication with hydromorphone (O.l 
mg/kg [0.045 mg/lb], IM) was effective in preventing 
vomiting and signs of nausea. However, SC injection 
of maropitant has been associated with pain, especially 
when the drug has been stored according to label in-
structions at room temperature (approx 20° to 25°C).27 
Intravenous administration of maropitant constitutes 
extralabel usage and has been associated with hypoten-
sion in dogs and cats. 28•29 Maropitant tablets adminis-
tered at a minimum dosage of 2.0 mg/kg (0.9 mg/lb) 
orally once a day are labeled for the prevention of acute 
vomiting in dogs; such oral administration would pro-
vide a nonpainful treatment option (compared with SC 
administration of the drug) and avoid development of 
cardiovascular adverse effects. Therefore, the goal of 
the study reported here was to evaluate the effective-
ness of administration of the oral formulation of ma-
ropitant citrate in preventing vomiting associated with 
hydromorphone hydrochloride administration in dogs. 
Materials and Methods 
Study population-The study was approved by 
the Iowa State University Institutional Animal Care 
and Use Committee. The owners of dogs brought to the 
Lloyd Veterinary Medical Center at Iowa State Univer-
sity College of Veterinary Medicine were asked to par-
ticipate in this study if their dogs were healthy, weighed 
between 24 and 60 kg (52.8 and 132.0 lb), were being 
admitted for elective anesthesia and surgery, and would 
be receiving hydromorphone as an anesthetic premedi-
cation drug. Staff and students of Iowa State Univer-
sity College of Veterinary Medicine were contacted via 
college-wide electronic mail to enroll their own dogs if 
they were healthy and weighed between 24 and 60 kg 
in exchange for a CBC and routine serum biochemi-
cal analysis. All owners provided informed consent for 
participation. The study included 40 dogs > 6 months 
of age that were classified as American Society of Anes-
thesiologists status I (healthy with no systemic disease) 
or status II (nonincapacitating systemic disease), as 
determined from the results of complete physical ex-
amination, CBC, and routine serum biochemical analy-
sis. 30 Among the 40 dogs, there were 22 female dogs (19 
spayed and 3 sexually intact) and 18 male dogs (17 cas-
trated and 1 sexually intact); the dogs were 11 months 
to 9.3 years of age and weighed 24 to 58.2 kg (52.8 to 
128.04 lb). The dogs were mixed-breed and purebred 
dogs. Twenty-two dogs were owned by clients, and 18 
dogs were owned by staff or students of the Iowa State 
University College of Veterinary Medicine. 
Experimental treatment-The Iowa State Univer-
sity College of Veterinary Medicine Lloyd Veterinary 
Medical Center pharmacy compounded colored gelatin 
capsules to allow the study to be performed in a blinded 
manner; only pharmacy staff had the key to what was 
contained in each capsule. Dogs were randomly as-
signed by simple randomization with a card draw tech-
nique to receive 1 or 2 orange capsules containing 60 
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mg of maropitant citrate' (n = 20) once or 1 or 2 white 
capsules containing 400 mg of lactose monohydrateb 
(placebo; 20) once. In accordance with the maropitant 
package insert dosing instructions ,31 dogs received 1 or 
2 maropitant or placebo capsules on the basis of weight. 
Dogs that weighed 24 to 30 kg (52.8 to 66 lb) received 
1 capsule, and dogs 30 .1 to 60 kg ( 66. 22 to 13 2 lb) re-
ceived 2 capsules. For dogs in the maropitant treatment 
group, this corresponded to a drug dose of 2.0 to 2.5 
mg/kg (0.9 to 1.14 mg/lb) for dogs that weighed 24 to 
30 kg and a drug dose of 2.0 to 4.0 mg/kg (0.9 to 1.82 
mg/lb) for dogs that weighed 30.1 to 60 kg. 
Oral dosing instructions for maropitant indicate 
that it should be administered with a small amount of 
food; therefore, the maropitant capsules were adminis-
tered with 1 tablespoon of canned dog food.< Dogs that 
refused the capsule (or capsules) and food were admin-
istered the capsule (or capsules) by hand without food. 
Twenty dogs received treatment with maropitant; 10 of 
those dogs received th e capsule (or capsules) with food, 
and 10 had the capsule (or capsules) administered by 
hand without food. Twenty dogs received placebo; 10 
received the capsule (or capsules) with food, and 10 
had the capsule (or capsules) administered by hand 
without food. Dogs were administered maropitant or 
placebo 2 hours prior to receiving hydromorphone (O.l 
mg/kg, IM) in the lumbar epaxial muscles. 
Data collection-A trained observer (BLHK) blind-
ed to treatment group documented the presence or ab-
sence of emetic events, total number of discrete emetic 
events, presence or absence of signs of nausea, and se-
verity of signs of nausea for each dog during a 30-min-
ute period following administration of hydromorphone. 
Vomiting was defined by expulsion of stomach contents 
from the mouth. Signs interpreted as nausea included 
salivation, increased frequency of or exaggerated swal-
lowing motions, and licking of lips. Signs of nausea were 
subjectively graded as none, mild, moderate , or severe; 
the maximal severity of signs of nausea noted during the 
30-minute period was recorded for each dog. 
Statistical analysis-The primary variable used in 
the analysis of efficacy was whether a dog had 2 1 vomit-
ing episodes. A 2-tailed Fisher exact test was performed 
to compare the incidence of vomiting between the ma-
ropitant and placebo treatment groups. The Fisher exact 
test was repeated with the inclusion of signs of nausea in 
addition to vomiting. Significance was assessed at a value 
of P ~ 0.05. A t test was used to detect incidental dif-
ferences between the groups that may have occurred on 
the basis of age and weight. A Mann-Whitney U test was 
used to compare the overall severity of signs of nausea 
between the maropitant and placebo treatment groups; 
for this analysis, severity grades were assigned numeri-
cal values as follows: no signs of nausea, O; mild signs of 
nausea, l; moderate signs of nausea, 2; and severe signs 
of nausea, 3. A Fisher exact test was run to compare the 
incidence of vomiting and nausea between male and fe-
male dogs in the placebo treatment group. 
Results 
For the 20 dogs that were administered maropitant, 
the mean± SD age was 4.4 ± 2.4 years and mean weight 
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was 35 ± 9.3 kg (77 ± 20.46 lb); there were 7 males and 
13 females in this group. For the 20 dogs that were ad-
ministered the placebo, the mean age was 5.0 ± 2.7 years 
and mean weight was 34.9 ± 7.2 kg (76.8 ± 15.84 lb); 
there were 11 males and 9 females in this group. There 
was no significant difference in age (P = 0.429), weight 
(P = 0.978), or sex distribution (P = 0.34) between the 
maropitant- and placebo-treated dogs. 
Among the dogs that received maropitant, there 
was no significant difference in the number of dogs that 
did or did not vomit (P = 1.0) or that did or did not 
develop signs of nausea (P = 0.65) between dogs that 
received the treatment with food or received the treat-
ment by hand without food. Likewise, among dogs that 
received placebo, there was no significant difference in 
the number of dogs that did or did not vomit (P = 1.0) 
or that did or did not develop signs of nausea (P = 0.58; 
Table 1) between dogs that received the treatment with 
food or received the treatment by hand without food. 
Thus, for the maropitant or placebo treatment group, 
the data from the fed and hand-dosed dogs were pooled 
to increase the power of the study. 
In the placebo treatment group, there was no dif-
ference between males and females with regard to the 
incidence of vomiting (P = 0.319) or number of dogs 
with signs of nausea (P = 1.0). Among the 20 placebo-
treated dogs, 5 ( 4 males and 1 female; 25%) vomited 
and 16 (9 males and 7 females; 80%) developed signs 
of nausea. Of the 5 dogs that vomited in the placebo 
treatment group, 2 vomited only once and 3 vomited> 
1 time. In the maropitant treatment group, none of the 
20 dogs vomited; however, 12 (60%) developed signs 
of nausea. Orally administered maropitant significantly 
decreased the incidence of vomiting (P = 0.04 7) but not 
the incidence of signs of nausea (P = 0.301), compared 
with the effects of placebo, in the study dogs. 
In the maropitant treatment group, 8 of 20 dogs did 
not develop signs of nausea. Among the 12 maropitant-
treated dogs that developed signs of nausea, severity 
was subjectively graded as mild for 2, moderate for 4, 
and severe for 6. Overall, signs of nausea were moderate 
to severe in 10 of the 12 dogs. In the placebo treatment 
group, 4 of the 20 dogs did not develop signs of nau-
sea. Among the 16 placebo-treated dogs that developed 
signs of nausea, severity was graded as mild for 14 and 
moderate for 2; none of the dogs had signs of nausea 
graded as severe. Overall, signs of nausea were mild in 
14 of the 16 dogs. However, there was no significant (P 
= 0.363) difference in the overall subjective grading of 
severity of signs of nausea between the maropitant and 
placebo treatment groups. 
Discussion 
The results of the present study indicated that the 
oral formulation of maropitant citrate, administered 
at a dose (minimum, 2.0 mg/kg, PO) specified for the 
prevention of acute vomiting in the label instructions , 
was effective in preventing vomiting in dogs receiving 
hydromorphone hydrochloride (O .l mg/kg, IM) . This 
finding correlated well with results of a recent study9 
of the injectable formulation given at a dose of 1.0 mg/ 
kg, SC, 1 hour prior to administration of hydromor-
phone in dogs. Subcutaneous injection of maropitant 
may be associated with pain, which is a particular prob-
lem when the injectable solution is stored at room tem-
perature. The drug solution is formulated with sulfobu-
tylether-cyclodextrin, with which maropitant forms a 
molecular complex that provides higher drug solubility 
and improved injection-site tolerance; at warmer tem-
peratures, there is greater complex dissociation. 27 It is 
suggested that the injectable form of maropitant should 
be refrigerated until administration to minimize injec-
tion reactions. 27 Recent studies28•29 that investigated the 
minimal alveolar concentration-sparing effects of ma-
ropitant indicate that extralabel IV administration of 
maropitant may cause hypotension in both dogs and 
cats. Oral administration of the drug avoids injection-
associated pain, the need for refrigeration of the drug 
solution, issues with extralabel usage, and cardiovas-
Table 1-Number of dogs that vomited or developed signs of nausea after administration of maropitant 
citrate (2.0 to 4.0 mg/kg 10.9 to 1.8 mg/lb]; n = 20) or placebo (lactose monohydrate; 20) with food (10 
dogs/treatment group) or by hand without food (10 dogs/treatment group) 2 hours before administra-
tion of hydromorphone hydrochloride (0.1 mg/kg 10.045 mg/lb], IM). 
1166 
Maropitant Placebo 
Variable With food Without food Pvalue* With fo od Without food Pvalue* 
Vomiting 0 0 1.0 2 3 1.0 
No vomiting 10 10 8 7 
Signs of nausea 7 5 0.65 9 7 0.58 
No signs of nausea 3 5 1 3 
Dogs (owned by clients [n = 22] or facility staff and students (18]) were classified as American Society of Anes-
thesiologists status I (healthy with no systemic disease) or status II (mild systemic disease but no functional limita-
tions). Dogs rece ived 1 or 2 orange capsules containing 60 mg of maropitant citrate once or 1 or 2 white capsules 
containing 400 mg of lactose monohydrate once; dogs that weighed 24 to 30 kg (58.2 to 66 lb) received 1 capsule and 
dogs that weighed 30.1 to 60 kg (66.22 to 132 lb) received 2 capsules. For dogs in the maropitant treatment group, 
this corresponded to a drug dose of 2.0 to 2.5 mg/kg (0.9 to 1.14 mg/lb) for dogs that weighed 24 to 30 kg and a drug 
dose of 2.0 to 4.0 mg/kg for dogs that weighed 30.1 to 60 kg. Treatment was given with or without 1 tablespoon of 
canned dog food. For each treatment group, the number of dogs that vomited (expulsion of stomach contents from 
the mouth) or developed signs of nausea (including salivation, increased frequency of or exaggerated swallowing 
motions, and licking of lips) during a 30-minute period after hydromorphone administration was recorded. 
*Values of ?indicate thatthere was no significant (P > 0.05) difference in number of dogs that vomited or num-
ber of dogs that developed signs of nausea when treated with or without food in either the maropitant or placebo 
treatment group. 
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cular adverse effects . Tablets can be administered to 
dogs by their owners at home, which may also provide 
a more convenient route and timing of treatment for 
the prevention of emesis prior to planned elective an-
esthesia and surgery that will involve administration of 
hydromorphone or other opioid drugs known to elicit 
vomiting. 
In the present study, orally administered maropi-
tant was more effective in preventing vomiting after 
hydromorphone administration in dogs than it was in 
previous experiments32 that used syrup of ipecac (pe-
ripherally acting emetogen) and apomorphine (cen-
trally acting emetogen) . In those experiments,32 orally 
administered maropitant administered to dogs at a min-
imum dose of 2.0 mg/kg 1 hour prior to administration 
of a known emetogen significantly reduced but did not 
eliminate the incidence of vomiting. Pharmacokinetic 
data23 indicate that the plasma concentration of ma-
ropitant is maximal at 1.9 hours after oral administra-
tion of a 2.0 mg/kg dose. Therefore, the effectiveness of 
maropitant in the prevention of vomiting induced by 
a known emetogen may be increased if an interval of 
2 hours is allowed to elapse between the 2 treatments. 
Despite the effectiveness of maropitant in prevent-
ing vomiting in the present study, there was no sig-
nificant difference in the incidence of signs of nausea 
between maropitant- and placebo-treated dogs. In a 
study evaluating treatment of motion sickness in dogs 
by Benchaoui et al, 33 maropitant (8.0 mg/kg [3.64 mg! 
lb], PO) administered 1 hour prior to a car ride did 
not have an effect on the incidence of signs of nausea. 
Hypersalivation and retching were reported as the most 
common adverse effects (9117 dogs) in field studies31 ·32 
of the safety and efficacy of maropitant administration 
(8.0 mg/kg, PO) 1 hour prior to transportation for the 
prevention of motion sickness. Similar findings were 
reported when dogs were administered apomorphine 
1 hour after administration of maropitant (2.0 mg/kg, 
PO) , in which visual analog scores for signs of nausea for 
maropitant-treated dogs were not significantly different 
from those for placebo-treated dogs except at the 3- and 
6-minute time points.32 However, hypersalivation was 
not reported as an adverse reaction in field studies31 ·32 
of the prevention of acute vomiting in dogs treated with 
maropitant tablets at a minimum dosage of 2.0 mg/kg, 
PO, once daily for up to 5 consecutive days. Dogs in the 
present study were not specifically observed for signs 
of nausea during the interval between administration 
of the maropitant or placebo capsule (or capsules) and 
administration of hydromorphone. A limitation of this 
study was the ability to discern between signs of nau-
sea caused by maropitant and signs of nausea caused 
by hydromorphone. A distinct advantage of injection of 
maropitant over oral administration is the prevention 
of signs of nausea when treatment is provided 1 hour 
prior to administration of hydromorphone. 9 
In the present study, there was no significant differ-
ence in the overall subjective grading of the severity of 
signs of nausea between the maropitant- and placebo-
treated dogs. However, of the 12 dogs in the maropitant 
treatment group that did have signs of nausea, 10 were 
subjectively assessed as having moderate to severe signs 
indicating profuse salivation, whereas of the 16 dogs in 
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the placebo treatment group that did have signs of nau-
sea, 14 were subjectively assessed as having mild signs 
of nausea. Failure to illustrate a significant difference in 
the severity of signs of nausea between groups may in-
dicate that this simplified nausea scale lacked the speci-
ficity to accurately serve as a clinical assessment tool for 
signs of nausea in veterinary patients. To date , there are 
no available or validated nausea assessment scales in 
veterinary patients, to the author's knowledge. 
In the placebo treatment group, there was no differ-
ence between males and females with regard to the inci-
dence of vomiting or signs of nausea, which was in agree-
ment with findings of a previous study9 in dogs involving 
injectable maropitant. This is contrary to findings in hu-
mans, where being female imparts a 2- to 4-fold increase 
in risk, the strongest patient-related risk factor, for periop-
erative nausea and vomiting.34 Prepubescent girls lack this 
increased likelihood of perioperative nausea and vomit-
ing, which may imply that the risk is related to hormonal 
factors .34 All of the female dogs in the placebo treatment 
group in the present study were spayed, which may have 
eliminated any hormonal influences on sex differences in 
the incidence of nausea and vomiting. 
The incidence of vomiting associated with hy-
dromorphone administration in dogs was 25% in the 
study of this report. The reported incidence of vomit-
ing associated with hydromorphone administration 
ranged widely (0% to 100%) depending on the study 
conditions (withholding of food), study population, 
dose and route of administration, and concurrent use 
of acepromazine. 2.f>--9 Smith et al2 reported that no dogs 
vomited or developed signs of nausea when treated 
IM with either hydromorphone (0.22 mg/kg [0.1 mg/ 
lb]) alone or hydromorphone with acepromazine (0.05 
mg/kg [0.023 mg/lb]) . The dogs in that study2 were re-
search dogs, and food was not withheld prior to drug 
administration. Valverde et al6 reported that 5 of 10 
dogs vomited when hydromorphone (O.l mg/kg) and 
acepromazine (0.05 mg/kg) were administered IM at 
the same time and that administration of acepromazine 
15 minutes prior to hydromorphone decreased the inci-
dence of vomiting to 5 of 21 dogs, presumably because 
of the blockade of dopamine receptors in the chemore-
ceptor trigger zone. 6 The dogs in that study6 were client-
owned dogs undergoing elective surgery, and although 
the fact was not reported, the assumption is that food 
was withheld prior to planned clinical anesthesia. In 
the pharmacokinetic study involving healthy research 
Beagles by KuKanich et al,7 the incidence of vomiting 
varied with the dose and route of administration of hy-
dromorphone. At a dose of 0.1 mg/kg, IV, hydromor-
phone induced vomiting in 3 of 9 dogs, whereas 6 of 
8 dogs given the same dose SC vomited.7 Following IV 
administration of given 0.5 mg of hydromorphone/kg 
(0.23 mg of hydromorphone/lb) to 9 dogs, none vom-
ited; however, following SC administration of the same 
dose, 8 of 8 dogs vomited . 7 It is postulated that at lower 
doses or through slower absorption, opioids reach the 
chemoreceptor trigger zone but not the vomiting center 
and therefore result in emesis, whereas at higher doses 
or via IV administration, opioids reach the vomiting 
center and block the effects on the chemoreceptor trig-
ger zone.35 In a study by Hofmeister et al,8 only 5 of 23 
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(22%) dogs that received hydromorphone alone or with 
acepromazine vomited. The dogs in that study8 were 
random-source female dogs that were anesthetized at 
a surgical exercises laboratory for third-year veterinary 
students, and food was not withheld from the dogs 
prior to drug administration. In another study,9 6 of 9 
client-owned dogs from which food had been withheld 
vomited after administration of hydromorphone (O.l 
mg/kg , lM). The influence of dose and route of admin-
istration of opioid drugs on the incidence of vomiting is 
well established33 ; however, the influence of withhold-
ing food or the source of the study dogs on the inci-
dence of vomiting has not been as well established. Ac-
cording to Smith et al2 and Hofmeister et al,8 it appears 
that lack of food withholding decreases the incidence 
of vomiting associated with hydromorphone. In the 
present study, there was no significant difference in the 
incidence of vomiting regardless of whether the dogs 
received the study treatment with or without a small 
amount of food. However, for each experiment, food 
had been withheld from the dog from 10:00 PM the 
previous evening as per client instructions for dogs 
undergoing anesthesia. The small amount of food in-
cluded with the maropitant or placebo treatment may 
not have been sufficient to influence the incidence of 
vomiting. 
The source of the study dogs may be another im-
portant factor influencing the incidence of vomiting 
associated with hydromorphone. The incidence of 
vomiting in acclimated research dogs following treat-
ment with hydromorphone alone or in combination 
with acepromazine has been reported as 0%2 and 22%.8 
The present study involved 40 dogs, 22 (55%) of which 
were client owned and 18 ( 45%) of which were staff or 
student owned. Many of the staff- and student-owned 
dogs visited the Iowa State University College of Vet-
erinary Medicine Lloyd Veterinary Medical Center on 
a regular basis and therefore may have been acclimated 
to the environment and less anxious than the client-
owned dogs. In human patients, a higher anxiety level 
is significantly associated with a more frequent inci-
dence of perioperative vomiting and nausea.36 Fear, 
anxiety, memory, anticipation, and pain are known to 
be higher center inputs to the vomiting center and can 
elicit vomiting. These inputs to the nucleus tractus soli-
tarius from the cerebral cortex, triggered by fear and 
anxiety, along with visual afferents stimulate the emetic 
center directly. 37 The influence of fear and anxiety on 
the incidence of perioperative nausea and vomiting in 
dogs has not been studied, to the author's knowledge. 
Prevention of perioperative vomiting in dogs, espe-
cially those at higher risk for aspiration pneumonia (eg, 
brachycephalic dogs; dogs with neurologic dysfunction, 
head trauma, or suspected increased intracranial pres-
sure; and dogs undergoing intraocular surgery) , may 
have a clear advantage in avoidance of patient morbid-
ity and death. In this respect, both the injectable formu-
lation of maropitant administered at 1.0 mg/kg, SC, 1 
hour prior to opioid premedication and the oral formu-
lation administered at a minimum dose of 2.0 mg/kg, 
PO, 2 hours prior to opioid premedication are equally 
effective in the prevention of vomiting.9 However, an 
additional consideration in veterinary patients may be 
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the prevention of signs of nausea. Humans undergoing 
anesthesia report high levels of discomfort and dissatis-
faction associated with perioperative nausea and vom-
iting. Both anesthesiologists and patients rate nausea 
and vomiting among the anesthesia outcomes to be 
most avoided, and it is considered by many patients to 
be more distressing than postsurgical pain. 38·39 ln fact, 
human patients are willing to spend up to $100 out of 
pocket for an effective antiemetic.40 The cost of injectable 
maropitant is approximately $0.20/kg ($0.09/lb), which 
would be $4.00 for a 20-kg (44-lb) dog. As veterinar-
ians, we cannot know with certainty that perioperative 
nausea and vomiting cause discomfort or distress for our 
patients, as it does for humans. Morton et al41 suggested 
the use of critical anthropomorphism to evaluate ani-
mal suffering, and indicated that where doubt exists in 
the interpretation of animal suffering, the benefit of the 
doubt should lie with the animal. That is, if a human is 
likely to experience discomfort or distress under particu-
lar conditions, then it should be assumed, unless there is 
clear evidence to the contrary, that an animal of another 
species may be similarly affected. 41 
Results of the present study have indicated that the 
incidence of vomiting associated with hydromorphone 
administration in a mixed group of 40 client- and staff-
or student-owned dogs from which food had been with-
held was only 25%. Oral administration of maropitant 
at a minimum dose of 2.0 mg/kg prevented vomiting 
but not development of signs of nausea when given 2 
hours prior to hydromorphone administration in dogs. 
a. Cerenia, Pfizer Animal Health, New York, NY. 
b. Lactose monohydrate, fisher Scientific, Pittsburgh, Pa. 
c. Purina Gastroenteric Canine formula, Vevey, Switzerland. 
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